Jasper's Basic Mechanisms, Fourth Edition, is the newest most ambitious and now clinically relevant publishing project to build on the four-decade legacy of the Jasper's series. In keeping with the original goal of searching for "a better understanding of the epilepsies and rational methods of prevention and treatment.", the book represents an encyclopedic compendium neurobiological mechanisms of seizures, epileptogenesis, epilepsy genetics and comordid conditions. Of practical importance to the clinician, and new to this edition are disease mechanisms of genetic epilepsies and therapeutic approaches, ranging from novel antiepileptic drug targets to cell and gene therapies.

Epilepsy is one of most frequent neurological disorders affecting about 50 million people worldwide and 50% of them have at least another medical problem in comorbidity; sometimes this is a the cause of the epilepsy itself or it is due to shared neurobiological links between epilepsy and other medical conditions; other times it is a long-term consequence of the antiepileptic drug treatment. The Comorbidities of Epilepsy offers an up-to-date, comprehensive overview of all comorbidities of epilepsy (somatic, neurological and behavioral), by international authorities in the field of clinical epileptology, with an emphasis on epidemiology, pathophysiology, diagnosis and management. This book includes also a critical appraisal of the methodological aspects and limitations of current research on this field. Pharmacological issues in the management of comorbidities are discussed, providing information on drug dosages, side effects and interactions, in order to enable the reader to manage these patients safely. The Comorbidities of Epilepsy is aimed at all health professionals dealing with people with epilepsy including neurologists, epileptologists, psychiatrists, clinical psychologists, epilepsy specialist nurses and clinical researchers. - Provides a comprehensive overview of somatic, neurological and behavioral co-morbidities of epilepsy - Discusses up-to-date management of comorbidities of epilepsy - Written by a group of international experts in the field

Although epilepsy is one of the nation's most common neurological disorders, public understanding of it is limited. Many people do not know the causes of epilepsy or what they should do if they see someone having a seizure. Epilepsy is a complex spectrum of disorders that affects an estimated 2.2 million Americans in a variety of ways, and is characterized by unpredictable seizures that differ in type, cause, and severity. Yet living with epilepsy is about much more than just seizures; the disorder is often defined in practical terms, such as challenges in school, uncertainties about social situations and employment, limitations on driving, and questions about independent living. The Institute of Medicine was asked to examine the public health dimensions of the epilepsies, focusing on public health surveillance and data collection; population and public health research; health policy, health care, and human services; and education for people with the disorder and their families, health care providers, and the public. In Epilepsy Across the Spectrum, the IOM makes recommendations ranging from the expansion of collaborative epilepsy surveillance efforts, to the coordination of public awareness efforts, to the engagement of people with epilepsy and their families in education, dissemination, and advocacy for improved care and services. Taking action across multiple dimensions will improve the lives of people with epilepsy and their families. The realistic, feasible, and action-oriented recommendations in this report can help enable short- and long-term improvements for people with epilepsy. For all epilepsy organizations and advocates, local, state, and federal agencies, researchers, health care professionals, people with epilepsy, as well as the public, Epilepsy Across the Spectrum is an essential resource.

Assembles world-class expertise on clinical and molecular imaging-derived biomarkers, presenting neuroimaging in epilepsy in a broad neuroscientific context.

Designed to provide a comprehensive but accessible introduction to epilepsy and seizure disorders, Epilepsy, 2nd edition provides state-of-the-art information in a concise format useful to a wide audience, from neurology residents to epilepsy fellows and practitioners. This illustrated guide to the assessment, diagnosis, and treatment of epilepsy is a valuable resource enabling clinicians to stay on top of the latest recommendations for best practice.

Perhaps the most important achievements in the field of epileptology in the past two decades have been in the neuroimaging and genetic breakthroughs as applied to patients with epilepsy. Indeed, neuroimaging has become a vital part in the study of epilepsy, affecting broad aspects of the disorder ranging from diagnosis and classification to treatment and prognosis. Neuroimaging in epilepsy encompasses many different approaches that have reached various levels of expertise across epilepsy centers worldwide. This book discusses every imaging modality used to gather information on epilepsy. Each technique is described by world experts and epilepsy centers worldwide.

This volume is a scholarly reference to published research results on the neurobiology and neuroanatomy of depression and the association of depression with disorders of the central nervous system. The book reviews and discusses aspects of recent research on the underlying mechanisms of depression, including neurotransmitter dysregulation, hypothal

The pharmacological fight against epilepsy began many centuries ago when Hippocrates discovered that the cause of epilepsy is natural, as opposed to supernatural and, as a consequence, must be treated with a natural remedy. Even though science has significantly progressed since that era, the challenge to find remedies for epilepsy is ever present. The aim of this particular volume is to offer an up-to-date review of the most recent advances in antiepileptic drug development, considered from various viewpoints: (i) general, by taking into account the size of refractory epilepsy and its related problems; (ii) experimental, by exploring the mechanisms of epileptogenesis and the possiblility of influencing it through drugs, and (iii) clinical, by describing the results obtained with compounds currently at an advanced stage of testing.